Tofersen is an antisense drug targeting the enzyme superoxide dismutase 1 (SOD1) that is injected directly into the spinal canal once a month, and is being tested in a form of the ...

After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for amyotrophic lateral sclerosis (ALS) – with an elevated status among its pipeline ...

In June 2023, Mr Thomas started tofersen, as part of an early access programme suitable for people with the SOD1 MND gene - he admitted he had to "battle" to gain access at a hospital in England ...

Paula Trefiak was one of the first ALS patients to take the drug tofersen as part of a clinical trial. Her experience shows why its approval is generating so much excitement. Trump strikes new ...